

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition obtainable that can be obtained by mixing at least one active ingredient comprising a 17- β -estradiol or ethinylestradiol with at least one extrusion additive from a polyalcohol the group of polyalcohols esterified with a fatty acid acids wherein the extrusion additive comprises a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, and an adjuvant comprising polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof and joint melt extruding ~~extrusion~~.

2. (Canceled)

3. (Canceled)

4. (Currently Amended) A pharmaceutical composition ~~Pharmaceutical~~ compositions according to claim 1, wherein the fatty acid has ~~acids have~~ 1 to 31 carbon atoms and are unbranched and/or branched and/or saturated and/or unsaturated.

5. (Canceled)

6. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition according to claim ~~Claim~~ 1, wherein the melt extrusion is carried out without additional heat

input.

7. (Currently Amended) A pharmaceutical ~~Pharmaceutic~~ composition according to claim 1 wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable that can be obtained by mixing 17- β -estradiol, polyvinylpyrrolidone and saccharose monopalmitate and joint melt extruding ~~extrusion~~ at 60°C.

8. (Currently Amended) A pharmaceutical ~~Pharmaceutic~~ composition according to claim 1 wherein the extrusion additive is glycerol tribehenate and the composition is obtainable that can be obtained by mixing 17- β -estradiol, polyvinylpyrrolidone and glycerol tribehenate and joint melt extruding ~~extrusion~~ at 60°C.

9. (Currently Amended) A pharmaceutical ~~Pharmaceutic~~ composition according to claim 1 wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable that can be obtained by mixing ethinylestradiol, polyvinylpyrrolidone and saccharose monopalmitate and joint melt extruding ~~extrusion~~ at 60°C.

10. (Currently Amended) A process ~~Process~~ for the production of a pharmaceutical composition comprising joint melt extruding a mixture comprising compositions ~~in which~~ at least one active ingredient of 17- β -estradiol or ethinylestradiol is mixed with at least one extrusion additive ~~from the group of a polyalcohol polyalcohols~~ esterified with a fatty acid acids, and the mixture that is thus obtained is then subjected to a joint melt extrusion.

11. (Currently Amended) A process ~~Process~~ according to claim 10, wherein the melt extrusion is carried out without heat input.

12. (Currently Amended) A process ~~Process~~ according to claim 10, further comprising grinding wherein in addition, the extruded mixture is ~~ground~~ and ~~further processed~~ processing into a pharmaceutical agent ~~agents~~ with a ~~additional~~ pharmaceutically compatible adjuvant or additive ~~adjuvants and additives~~.

13. (Currently Amended) A pharmaceutical agent comprising ~~Pharmaceutical agents that contain~~ a pharmaceutical composition according to claim 1 and a ~~together with additional~~ pharmaceutically compatible adjuvant or additive ~~adjuvants and additives~~.

14. (Canceled)

Please add the following new claims:

--15. (New) A process according to claim 11, further comprising grinding the extruded mixture and processing into a pharmaceutical agent with a pharmaceutically compatible adjuvant or additive.

16. (New) A pharmaceutical composition according to claim 1, wherein the composition comprises a low-dose amount of the at least one active ingredient.

17. (New) A pharmaceutical composition according to claim 1, wherein the composition comprises 0.025% of at least one active ingredient relative to a single dose.

18. (New) A pharmaceutical composition according to claim 1, wherein the extrusion additive is from polyalcohols esterified with fatty acids.

19. (New) A pharmaceutical composition according to claim 1, wherein the extrusion additive consists of a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, the at least one active ingredient consists of 17- β -estradiol or ethinylestradiol, and the adjuvant consists of polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer, or a mixture thereof.

20. (New) A pharmaceutical composition obtainable by extruding a mixture comprising 17- β -estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

21. (New) A process according to claim 10, wherein the extrusion additive is from polyalcohols esterified with fatty acids.

22. (New) A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a solid dispersion.

23. (New) A mixture comprising 17- β -estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.--